OMIC - Singular Genomics Systems, Inc. Stock Price, Fair Value and News

0.38USD+0.01 (+2.70%)Delayed

Market Summary

USD0.38+0.01

Delayed

2.70%

OMIC Stock Price

View Fullscreen

OMIC RSI Chart

OMIC Valuation

Market Cap

28.2M

Price/Earnings (Trailing)

-0.29

Price/Sales (Trailing)

2.95

Price/Free Cashflow

-0.35

OMIC Price/Sales (Trailing)

OMIC Profitability

Operating Margin

63.13%

Return on Equity

-61.4%

Return on Assets

-40.24%

Free Cashflow Yield

-285.02%

OMIC Fundamentals

OMIC Revenue

Revenue (TTM)

9.6M

Rev. Growth (Yr)

-48.78%

Rev. Growth (Qtr)

-93.05%

OMIC Earnings

Earnings (TTM)

-96.2M

Earnings Growth (Yr)

-5.89%

Earnings Growth (Qtr)

-7.63%

Breaking Down OMIC Revenue

Last 7 days

-7.3%

Last 30 days

-5%

Last 90 days

-30.9%

Trailing 12 Months

-52.5%

How does OMIC drawdown profile look like?

OMIC Financial Health

Current Ratio

10.35

Debt/Equity

0.05

Debt/Cashflow

-10.41

OMIC Investor Care

Shares Dilution (1Y)

2.86%

Diluted EPS (TTM)

-1.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.6M	0	0	0
2023	4.1M	5.9M	5.3M	10.0M
2022	758.0K	773.0K	1.8M	3.4M
2021	531.3K	598.5K	665.8K	733.0K
2020	0	0	0	464.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Singular Genomics Systems, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	ropp sam	acquired	-	-	4,187	chief commercial officer
Mar 15, 2024	spaventa andrew	gifted	-	-	-14,583	chief executive officer
Mar 15, 2024	spaventa andrew	acquired	-	-	14,583	chief executive officer
Mar 15, 2024	spaventa andrew	gifted	-	-	14,583	chief executive officer
Mar 15, 2024	glezer eli n.	acquired	-	-	7,500	chief scientific officer
Mar 15, 2024	meeter dalen	acquired	-	-	6,250	chief financial officer
Dec 15, 2023	meeter dalen	acquired	-	-	6,250	chief financial officer
Dec 15, 2023	glezer eli n.	acquired	-	-	7,500	chief scientific officer
Dec 15, 2023	spaventa andrew	gifted	-	-	14,583	chief executive officer
Dec 15, 2023	spaventa andrew	acquired	-	-	14,583	chief executive officer

Which funds bought or sold OMIC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Engineers Gate Manager LP	unchanged	-	814	7,734	-%
May 15, 2024	Tikvah Management LLC	unchanged	-	17,141	162,926	0.05%
May 15, 2024	Casdin Capital, LLC	unchanged	-	71,623	680,742	0.05%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-12.87	-83.00	3,061	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-5,778	-	-%
May 15, 2024	ARCH Venture Management, LLC	unchanged	-	205,522	1,953,410	2.43%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	49.33	36,272	90,499	-%
May 15, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	115,065	1,093,650	0.02%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	6,573	62,475	-%
May 15, 2024	ORBIMED ADVISORS LLC	unchanged	-	29,251	278,026	-%

Are Funds Buying or Selling OMIC?

Are funds buying OMIC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OMIC

No. of Funds

Unveiling Singular Genomics Systems, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	spaventa andrew	7.9%	5,958,096	SC 13G/A
Feb 14, 2024	glezer eli n.	6.6%	4,872,083	SC 13G/A
Feb 12, 2024	flynn james e	0.00%	0	SC 13G/A
Jan 25, 2024	domain partners ix, l.p.	5.1%	3,763,985	SC 13G/A
Aug 14, 2023	flynn james e	0.55%	401,784	SC 13G/A
Feb 14, 2023	revelation alpine, llc	1.7%	1,184,497	SC 13G/A
Feb 14, 2023	spaventa andrew	6.7%	4,873,307	SC 13G/A
Feb 14, 2023	glezer eli n.	6.0%	4,299,583	SC 13G/A
Feb 10, 2023	flynn james e	2.05%	1,466,000	SC 13G/A
Feb 14, 2022	revelation alpine, llc	6.9%	4,988,602	SC 13G

Recent SEC filings of Singular Genomics Systems, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
Apr 18, 2024	ARS	ARS
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	DEFA14A	DEFA14A
Apr 05, 2024	PRE 14A	PRE 14A

Peers (Alternatives to Singular Genomics Systems, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Singular Genomics Systems, Inc. News

Latest updates

Singular Genomics Systems, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-93.0%	442	6,357	462	2,295	863	1,672	1,115	428	156	105	84.00	413	131	104	76.00	156
Cost Of Revenue	-44.0%	861	1,538	527	597	807	789	-	-	-	-	-	-	-	-	-	-
Gross Profit	8.3%	-419	-457	-65.00	-92.00	56.00	-24.00	-	-	-	-	-	-	-	-	-	-
Operating Expenses	6.5%	26,429	24,824	24,474	27,511	25,434	22,506	24,694	24,243	22,020	19,673	17,461	13,883	10,262	-	7,778	6,768
S&GA Expenses	13.7%	14,935	13,134	13,254	14,887	13,204	11,746	11,962	12,182	11,375	10,218	8,551	6,201	3,654	-	1,698	1,443
R&D Expenses	-1.7%	11,494	11,690	11,220	12,624	12,230	10,761	12,732	12,061	10,645	9,455	8,910	7,682	6,608	-	6,080	5,325
Interest Expenses	-1.0%	284	287	285	270	259	243	211	167	142	192	234	232	188	-	202	235
Net Income	-7.6%	-25,024	-23,249	-22,360	-25,578	-23,633	-21,101	-23,790	-23,982	-22,006	-19,760	-17,611	-37,479	-23,921	-7,115	-7,933	-6,847
Net Income Margin	-5.9%	-10.07*	-9.50*	-17.51*	-15.83*	-22.68*	-26.96*	-49.63*	-107.84*	-127.78*	-134.75*	-129.37*	-127.73*	-86.24*	-	-	-
Free Cashflow	-23.0%	-23,728	-19,294	-16,923	-20,304	-18,096	-21,735	-22,913	-27,690	-20,778	-17,469	-12,597	-16,807	-9,692	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-9.9%	239	265	285	284	305	328	345	366	342	356	371	384	31.00
Current Assets	-13.4%	166	192	211	226	246	268	286	306	326	348	364	379	28.00
Cash Equivalents	52.2%	25.00	16.00	33.00	75.00	129	74.00	95.00	155	190	202	240	258	12.00
Inventory	-3.6%	13.00	14.00	13.00	14.00	17.00	18.00	17.00	12.00	6.00	3.00	-	-	-
Net PPE	1.2%	14.00	14.00	13.00	11.00	11.00	11.00	10.00	9.00	7.00	6.00	5.00	3.00	2.00
Liabilities	-4.7%	82.00	86.00	85.00	66.00	65.00	68.00	69.00	69.00	25.00	19.00	19.00	17.00	13.00
Current Liabilities	-12.1%	16.00	18.00	15.00	14.00	12.00	14.00	14.00	13.00	9.00	7.00	6.00	8.00	4.00
Long Term Debt	-14.3%	8.00	9.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	6.00	8.00
LT Debt, Current	100.1%	3.00	1.00	-	-	-	-	-	-	-	-	-	3.00	1.00
LT Debt, Non Current	-100.0%	-	9.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	6.00	8.00
Shareholder's Equity	-12.5%	157	179	199	218	240	260	277	298	317	336	352	367	-
Retained Earnings	-7.4%	-362	-337	-314	-292	-266	-242	-221	-197	-173	-151	-132	-114	-53.12
Additional Paid-In Capital	0.6%	519	516	514	511	507	504	500	496	492	488	484	481	2.00
Shares Outstanding	0.3%	74.00	74.00	73.00	73.00	72.00	72.00	71.00	71.00	71.00	72.00	39.00	22.00	-
Float	-	-	-	-	49.00	-	-	-	214	-	-	-	1,300	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-25.4%	-23,703	-18,902	-16,813	-19,998	-17,934	-19,917	-21,786	-25,552	-19,839	-15,699	-10,976	-15,841	-9,185	-	-	-
Share Based Compensation	7.8%	2,896	2,687	2,794	2,842	3,081	3,099	3,399	3,605	3,566	2,935	2,859	2,341	1,096	-	-	-
Cashflow From Investing	4750.8%	31,579	651	-24,703	-35,086	72,945	171	-38,117	-10,006	8,386	-23,325	-5,709	-11,366	-90,461	-	-	-
Cashflow From Financing	-100.0%	-	72.00	-	618	6.00	750	27.00	101	23.00	810	-1,320	239,154	133,484	-	-	-
Buy Backs	-100.0%	-	6.00	-	6.00	7.00	-35.00	53.00	421	11.00	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OMIC Income Statement

2024-03-31

Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 442	$ 863
Cost of revenue	861	807
Gross margin	(419)	56
Operating expenses:
Research and development	11,494	12,230
Selling, general and administrative	14,935	13,204
Total operating expenses	26,429	25,434
Loss from operations	(26,848)	(25,378)
Other income (expense):
Interest income	2,108	2,004
Interest expense	(284)	(259)
Total other income	1,824	1,745
Net loss	$ (25,024)	$ (23,633)
Basic and diluted net loss per share, Basic	$ (0.34)	$ (0.33)
Basic and diluted net loss per share, Diluted	$ (0.34)	$ (0.33)
Weighted Average Number of Shares Outstanding, Basic	73,925,966	71,926,412
Weighted Average Number of Shares Outstanding, Diluted	73,925,966	71,926,412

OMIC Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 24,109	$ 16,233
Short-term investments	126,629	157,708
Accounts receivable	137	565
Inventory, net	13,081	13,572
Prepaid expenses and other current assets	2,519	4,150
Total current assets	166,475	192,228
Right-of-use lease assets	57,094	57,797
Property and equipment, net	13,854	13,692
Restricted cash	600	600
Other noncurrent assets	1,078	1,150
Total assets	239,101	265,467
Current liabilities:
Accounts payable	2,012	2,587
Accrued expenses	3,265	6,079
Lease liabilities, current	7,822	7,764
Other current liabilities	2,980	1,857
Total current liabilities	16,079	18,287
Lease liabilities, non current	58,092	58,623
Long-term debt, net of issuance costs	7,627	8,901
Other noncurrent liabilities	605	650
Total liabilities	82,403	86,461
Commitments and contingencies (Note 9)
Stockholders' equity:
Common stock, $0.0001 par value; 400,000,000 shares authorized, 74,067,366 and 73,823,161 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	7	7
Additional paid-in capital	519,361	516,439
Accumulated other comprehensive gain (loss)	(51)	155
Accumulated deficit	(362,619)	(337,595)
Total stockholders' equity	156,698	179,006
Total liabilities and stockholders' equity	239,101	265,467
Series A Common Stock Equivalent Convertible Preferred Stock [Member]
Stockholders' equity:
Series A common stock equivalent convertible preferred stock, $0.0001 par value; 7,000 shares authorized, 2,500 shares issued and outstanding at March 31, 2024 and December 31, 2023	$ 0	$ 0

About Singular Genomics Systems, Inc.

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.

CEO	Mr. Andrew Spaventa
WEBSITE	https://singulargenomics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	269

Singular Genomics Systems, Inc. Frequently Asked Questions

What is the ticker symbol for Singular Genomics Systems, Inc.? What does OMIC stand for in stocks?

OMIC is the stock ticker symbol of Singular Genomics Systems, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Singular Genomics Systems, Inc. (OMIC)?

As of Fri May 17 2024, market cap of Singular Genomics Systems, Inc. is 28.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OMIC stock?

You can check OMIC's fair value in chart for subscribers.

What is the fair value of OMIC stock?

You can check OMIC's fair value in chart for subscribers. The fair value of Singular Genomics Systems, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Singular Genomics Systems, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OMIC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Singular Genomics Systems, Inc. a good stock to buy?

The fair value guage provides a quick view whether OMIC is over valued or under valued. Whether Singular Genomics Systems, Inc. is cheap or expensive depends on the assumptions which impact Singular Genomics Systems, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMIC.

What is Singular Genomics Systems, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OMIC's PE ratio (Price to Earnings) is -0.29 and Price to Sales (PS) ratio is 2.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMIC PE ratio will change depending on the future growth rate expectations of investors.